Friday, March 10, 2017 7:11:08 PM
The price per share of our common stock being offered may be higher than the net tangible book value per share of our outstanding common stock prior to this offering. Assuming that an aggregate of 6,172,839 shares of our common stock are sold at a price of $3.24 per share, the last reported sale price of our common stock on The Nasdaq Capital Market on March 9, 2017, for aggregate gross proceeds of approximately $20.0 million, and after deducting commissions and estimated offering expenses payable by us, new investors in this offering will incur immediate dilution of 1.94 per share. For a more detailed discussion of the foregoing, see the section entitled “Dilution” below. To the extent outstanding stock options or warrants are exercised, there will be further dilution to new investors. In addition, to the extent we need to raise additional capital in the future and we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering.
Recent EVOK News
- Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications • GlobeNewswire Inc. • 04/17/2024 12:30:27 PM
- Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer • GlobeNewswire Inc. • 03/21/2024 08:15:59 PM
- Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/14/2024 08:05:28 PM
- Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024 • GlobeNewswire Inc. • 03/07/2024 09:10:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:15:06 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/20/2024 09:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 02:00:04 PM
- Evoke Pharma Announces Closing of $7.5 Million Public Offering • GlobeNewswire Inc. • 02/14/2024 12:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:35 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/09/2024 10:14:30 PM
- Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million • GlobeNewswire Inc. • 02/09/2024 12:30:48 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/09/2024 05:15:05 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/08/2024 11:50:59 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/11/2024 02:38:48 AM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/04/2024 09:30:47 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/19/2023 01:30:35 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 12/15/2023 09:30:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 02:00:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:30:08 PM
- Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent • GlobeNewswire Inc. • 11/27/2023 01:30:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:15:10 PM
- United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI • GlobeNewswire Inc. • 11/14/2023 01:30:28 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/09/2023 09:30:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 02:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:00:08 PM
FEATURED Glucotrack Announces Expansion of Its Continuous Glucose Monitoring Technology to Epidural Glucose Monitoring • Apr 17, 2024 8:00 AM
ILUS Provides Form 10-K Filing Update • ILUS • Apr 17, 2024 9:54 AM
Maybacks Global Entertainment To Fire Up 24 New Stations in Louisiana • AHRO • Apr 16, 2024 1:30 PM
Cannabix Technologies Begins Certification of Contactless Alcohol Breathalyzer, Re-Brands product series to Breath Logix • BLOZF • Apr 16, 2024 8:52 AM
Kona Gold Beverages, Inc. Acquires Surge Distribution LLC from Loud Beverage Group, Inc. (LBEV) • KGKG • Apr 16, 2024 8:30 AM
Branded Legacy, Inc. Reports Significant Net Income of Over $3.8 Million • BLEG • Apr 16, 2024 8:30 AM